Borchert, G., Kiire, C., Stone, N., Akil, H., Gkika, T., Fischer, M., . . . De Silva, S. (2024). Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Springer Nature [academic journals on nature.com].
Cita Chicago Style (17a ed.)Borchert, GA, et al. Real-world Six-month Outcomes in Patients Switched to Faricimab Following Partial Response to Anti-VEGF Therapy for Neovascular Age-related Macular Degeneration and Diabetic Macular Oedema. Springer Nature [academic journals on nature.com], 2024.
Cita MLA (9a ed.)Borchert, GA, et al. Real-world Six-month Outcomes in Patients Switched to Faricimab Following Partial Response to Anti-VEGF Therapy for Neovascular Age-related Macular Degeneration and Diabetic Macular Oedema. Springer Nature [academic journals on nature.com], 2024.